
Will Medicare Pay for Contact Lenses?
Original Medicare covers medical and hospital costs, but vision, dental, and hearing care aren't usually covered. This means you likely won't get financial help from Medicare to pay for your contact lenses.
However, there are a few exceptions. For example, Medicare may cover the cost of contact lenses after cataract surgery. And some Medicare Advantage plans provide vision coverage.
This article reviews how contact lenses might be covered under Medicare.
Does Medicare cover contact lenses?
While Medicare covers some vision services, it doesn't usually pay for eye exams or contact lenses. Some of the vision services that Original Medicare (parts A and B) may cover include:
an annual glaucoma test for people at high risk (including those with diabetes or a family history of glaucoma)
a yearly exam to test for diabetic retinopathy for those with diabetes
cataract surgery
diagnostic testing or screenings for macular degeneration
Medicare Part B coverage
Medicare Part B covers most outpatient medical services, such as doctor's visits, durable medical equipment, and preventive services. It doesn't usually cover contact lenses.
However, there is one exception. If you have cataract surgery, Medicare Part B will cover one pair of corrective contact lenses after your surgery.
When you have cataract surgery, your eye doctor will insert an intraocular lens, which can sometimes change your vision. As a result, you'll likely need new contact lenses or eyeglasses to correct your vision. Even if you wear glasses already, you'll most likely need a new prescription.
It's important to know that Medicare will pay for new contact lenses after each cataract surgery with an intraocular lens insertion. Normally, eye doctors will only perform surgery on one eye at a time. If you have surgery to correct a second eye, you can get another contact lens prescription at that time.
However, even in this situation, the contact lenses aren't totally free. You'll pay 20% of the Medicare-approved amount, and your Part B deductible applies.
Also, you'll have to make sure you order contacts from a Medicare-approved supplier. If you usually order your contact lenses from a certain supplier, be sure to ask if they accept Medicare. If not, you may need to find a new supplier.
Part C coverage
Medicare Advantage, or Medicare Part C, is an alternative to Original Medicare that combines Part A and Part B. To attract subscribers, Medicare Advantage plans offer some combination of dental, hearing, vision, and even fitness benefits.
Medicare Advantage plans can vary greatly in the vision coverage they offer. According to health policy research nonprofit KFF, 97% of Medicare Advantage plans offer some level of vision coverage in 2025.
Even with coverage, a person can still expect to have out-of-pocket costs. In 2018, Medicare Advantage enrollees who used their vision benefits spent an average of $194 on vision services.
Examples of services Medicare Advantage plans may cover related to vision include:
routine eye exams
exams for fitting frames or contact lens prescriptions
costs or copayments for contact lenses or eyeglasses
Medicare Advantage plans are often region-specific because many involve using in-network providers. To search for available plans in your area, visit Medicare.gov's coverage finder tool.
If you find a plan you're interested in, click on the 'Plan Details' button, and you'll see a list of benefits, including vision coverage. Often, you're required to purchase your contacts from an in-network provider to ensure the plan will cover them.
Costs and other savings options
The average cost of contact lenses can vary. Contacts range in features from daily disposable lenses to those that correct astigmatism, called toric lenses. In general:
Daily disposable lenses are more expensive than monthly lenses.
Multifocals are more expensive than distance-only or monovision lenses.
Toric contacts for astigmatism are more expensive than spherical contacts.
You'll also pay for accessories that help you care for your contacts. These can include contact lens cases, solutions, and eye drops — if you have dry eyes.
It's a little harder to get help paying for contacts compared to eyeglasses when you have vision needs.
Because glasses last longer than contacts and can be used and reused from donated materials, there are more organizations that may help you get a pair of free or low cost eyeglasses.
However, you can save money on your contacts through these approaches:
Order online: Many online contact lens retailers offer cost savings compared to ordering at a retail store. Just make sure you're using a reputable online source. You can also ask your retail store of choice if they'll match online prices.
Purchase an annual supply: Although there's a hefty upfront cost, purchasing an annual supply of contacts often offers the lowest cost in the end. This is particularly true when ordering from online retailers. Look into whether company rebates could help you save.
Look into Medicaid eligibility: Medicaid is a federal and state collaborative program that offers financial assistance for a number of medical costs, including vision and contact lenses. Eligibility is often income-based, and you can check your eligibility or learn how to apply on the Medicaid website. However, Medicaid may not cover contact lenses.
Safety tip for wearing contact lenses
When you do get your contacts, it's important that you use them as directed. Wearing them longer than recommended can increase your risk for eye infections, which can be both painful and costly to treat.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy
Early in my professional investing career, I learned that no matter how much you think you know, the market knows more. So while we should always try to assess where a stock or sector is headed, the better way to trade is with a simple framework: Any stock can go up and thus be a source of profits. However, owning each stock comes with different levels of risk, at different times. More News from Barchart Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Hedge Your Bets With This SPY Options Strategy While the VIX is Still Low Option Volatility And Earnings Report For Aug 18 – 22 Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. That's why, when I see a stock like United Healthcare (UNH), I remind myself, and you, that when a stock has been a headline-level bust all year, it sets up two scenarios. The first is that it has giant upside potential, as investors reconsider it. And, second is that it has about as much risk of major loss as it has just demonstrated. UNH's issues started with a horrific public tragedy, and then a self-induced set of behaviors and processes that put it in the crosshairs of regulators. And, in turn, investors. This month, some of those headwinds suddenly reversed, as major investors including Warren Buffett's Berkshire Hathaway (BRK.A) (BRK.B) and David Tepper's Appaloosa Management announced investment positions in the troubled healthcare giant and Dow Jones Industrial Average ($DOWI) member. But UNH is still facing a lot of issues. So, in my world, that means it's time to talk about collaring the stock using options, and pointing to Barchart's very well-organized and time-saving options data for help. UNH Stock Is an Ideal Options Collar Trade Here's why UNH is a great collar setup to me. The stock is way down, what I call a 'dog collar' situation. UNH dove in price with the market in early April, but its potential legal trouble surfaced around the time the S&P 500 Index ($SPX) and other broad market indicators rallied back. The stock has gone from approaching its all-time high in early April, to less than half its $600 high-water mark for 2025. Ah, but then the white knights of Wall Street appeared. And UNH is still a very robust business, a healthcare leader. So this creates a dichotomy of sorts. And increases the chances of a big move in either direction. This is exactly the best scenario for collars, if you are a risk manager like I insist on being. For those who believe that if you 'just buy and hold great stocks' everything will work out, UNH is a cautionary tale. Few, if any, stocks are immune to long stretches in which they do not produce any returns. In the case of UNH, its 12% pop on Friday brought its return for last week above 20%. Impressive. But that only brings it back to where it traded during the middle part of 2020! Risk happens, and it happens fast sometimes. Collaring Stocks Lets You Play Offense and Defense… At the Same Time! Collars are misunderstood by many investors. While they are designed to protect against loss below a certain price threshold over a set period of time, they do not have to represent lost upside potential. Because unless I spend all of my assets on that collar, if it blasts above the call strike price before expiration date, I can buy more stock. Or buy call options. So I'm not missing out on a 'flyer.' I just need to do more work to continue pursuing price growth above the call strike price. As I've written here many times, collaring stocks is hardly a one-size fits all process. Every stock is at least a little different, as are the option contract specifications available. UNH has a very active options market, especially after the events of the past several months. Many traders are trying to turn their beliefs about the stock into profits. I looked out to the second half of 2026, but the pricing was not much better than staying shorter term. So above you see one possibility, going out 6 months to February 2026. There's always a tradeoff an investor needs to accept with collaring stocks. In this example, that tradeoff is on the out-of-pocket cost, around 6%. That's the main 'risk' here, since the put strike price is $300, just below Friday's $304 closing price. So the downside is that cost plus a few dollars a share, or about 8%. For a stock down more than 50%. The upside is out to $380, which is where the stock had one of its 2025 meltdown moments, back in May. That now represents 18% upside before any capping of gains would occur. Risk Management Does Not Have to Mean Sacrificing Returns This is merely one example of what we can do if we step back for a moment and think of what investing is. To me, it is not so much about 'owning great companies,' since markets work differently now. They reward those who use the markets as a tool to pursue profits with high liquidity. And they also reward those who make risk management front and center in their investment decisions. Collaring stocks, especially those in turmoil, can be a very useful, flexible part of that toolbox. On the date of publication, Rob Isbitts did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
20 minutes ago
- Yahoo
Why GoodRx (GDRX) Stock Is Trading Up Today
What Happened? Shares of healthcare tech company GoodRx (NASDAQ:GDRX) jumped 40.2% in the afternoon session after the company announced a collaboration with pharmaceutical giant Novo Nordisk to offer the popular medications Ozempic and Wegovy for $499 per month to eligible self-paying customers. This landmark collaboration makes the popular GLP-1 medications—used for type 2 diabetes (Ozempic) and weight loss (Wegovy)—available at a significantly lower cost to those who lack adequate insurance coverage. According to the announcement, this marks the first time Ozempic has been offered at this self-pay price point. The offer is effective immediately and available through the GoodRx platform at over 70,000 retail pharmacies nationwide. Investors reacted positively, viewing the strategic partnership as a pivotal move that could substantially expand GoodRx's market reach and user base by capitalizing on the high-demand therapeutic category. Is now the time to buy GoodRx? Access our full analysis report here, it's free. What Is The Market Telling Us GoodRx's shares are very volatile and have had 27 moves greater than 5% over the last year. But moves this big are rare even for GoodRx and indicate this news significantly impacted the market's perception of the business. The biggest move we wrote about over the last year was about 2 months ago when the stock gained 5.7% on the news that the major indices rebounded (Nasdaq +1.4%, S&P 500 +1.0%) on hopes the reported ceasefire between Israel and Iran will hold. This de-escalation in a volatile region helped to ease concerns about potential disruptions to global oil supplies, leading to a notable dip in crude oil prices. Additionally, dovish signals from Federal Reserve Chair Jerome Powell in his Congressional testimony, reaffirming a "wait-and-see" approach on interest rates, further calmed markets, improving investors' appetite for stocks and other risk assets. GoodRx is up 12.9% since the beginning of the year, but at $5.15 per share, it is still trading 40.1% below its 52-week high of $8.59 from August 2024. Investors who bought $1,000 worth of GoodRx's shares at the IPO in September 2020 would now be looking at an investment worth $101.96. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Measles outbreak that sickened more than 700 declared over in Texas
A measles outbreak in Texas that infected more than 700 people has officially been declared over, state health officials announced on Monday. The outbreak was the largest in the state in more than 30 years and led to the deaths of two unvaccinated school-aged children. Health officials declared the outbreak over after more than 42 days without a new case, a cut-off based on the time between when a person is exposed to when they get sick. MORE: Measles cases in US over 4.5 times higher than all of last year In late January, a cluster of cases was reported in western Texas near Gaines County -- near the border with New Mexico -- which had one of the lowest vaccination rates in the state. A total of 762 cases were recorded with more than two-thirds of infections among children, according to the Texas Department of State Health Services (DSHS). Nearly 100 people were hospitalized. Infections spread to other parts of the state as well as New Mexico, where another unvaccinated person died after contracting measles. "I want to highlight the tireless work of the public health professionals across the state who contributed to the containment of one of the most contagious viruses," Dr. Jennifer Shuford, commissioner of the DSHS, said in a press release. "We arrived at this point through a comprehensive outbreak response that included testing, vaccination, disease monitoring and educating the public about measles through awareness campaigns." Texas health officials warned that the state is likely to experience additional cases this year given ongoing outbreaks in other parts of the U.S. and the world. "The end of this outbreak is certainly encouraging, but measles remains one of the most contagious viruses we face, and continued vigilance is critical given ongoing outbreaks both in the U.S. and globally," said Dr. John Brownstein, an epidemiologist and ABC News medical contributor. Nationally, over 1,350 cases of measles have been reported across at least 40 states, according to the Centers for Disease Control and Prevention (CDC). It is the highest number of measles cases seen in the U.S. since 1992. MORE: Amid growing Texas outbreak, how contagious is measles? The virus was declared eliminated by health officials in 2000 after a full year of no continuous spread, but declining vaccination rates have led to a growing number of outbreaks annually, experts say. An estimated 92% of cases nationally this year are unvaccinated or have unknown vaccination status. "Vaccination rates in many communities remain far too low, leaving large pockets of children vulnerable to measles and other preventable diseases -- and that's why we're likely to continue seeing outbreaks," Brownstein said. The 2024-2025 school year had a record number of non-medical vaccine exemptions, with an estimated 286,000 kindergarteners attending school without documentation of receiving the shot that protects against measles, according to CDC data. "Measles isn't happening in isolation -- we're seeing a broader resurgence of vaccine-preventable diseases, from pertussis to polio threats, which underscores the urgent need to maintain high vaccination coverage and public trust in immunization," Brownstein added. The measles, mumps and rubella (MMR) vaccine is recommended for children in the U.S. to receive after their first birthday, followed by a second dose in between ages four and six. Two doses of the vaccine have been shown to be 97% effective against infection. Solve the daily Crossword